1. Scrip
  2. >>Business

After Bad Data Comes Layoffs – Will The Next Job Cuts Be At Anthera?

 
• By Mandy Jackson

Anthera is exploring strategic alternatives after its lead drug candidate Sollpura failed in Phase III, which means layoffs may be coming soon. Several other biopharma companies have had to turn to job cuts already this year.

Desperate businessmen

Anthera Pharmaceuticals Inc. did not get the RESULT it was looking for in a Phase III clinical trial testing Sollpura in the treatment of exocrine pancreatic insufficiency (EPI) due to cystic fibrosis, so the company "plans to evaluate all strategic alternatives in order to maximize shareholder value."

That kind of language usually signals layoffs in the near term while biopharmaceutical firms determine whether they have any assets...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business

BIO Notebook: Woodcock Calls For Doing The Right Thing, Dealmaking Remains Constrained

 
• By Mandy Jackson, Joseph Haas, and Sarah Karlin-Smith

Highlights from Day Four of the BIO International Convention include Woodcock offering practical advice on rare disease trials, the sorry state of dealmaking mid-year, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.

Syncona Looks To Go Private As Market Decline Deepens

 
• By Andrew McConaghie

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.